Funding for this research was provided by:
ECOG-ACRIN Cancer Research Group (NA)
Stand Up To Cancer (NA)
Hyundai Hope On Wheels (NA)
Midwest Athletes Against Childhood Cancer (NA)
St. Baldrick's Foundation (NA)
University of Wisconsin Carbone Cancer Center (NA)
Forward Lymphoma Fund (NA)
ASH Trainee Research Award (NA)
U.S. Public Health Service (CA180820, CA180794, CA180799, CA180816, CA189859, CA180833, CA197078)
Received: 7 November 2018
Accepted: 20 February 2019
First Online: 12 March 2019
Ethics approval and consent to participate
: As approved in the initial clinical report (6), all patients signed approved consent forms. These associative analyses reported in this manuscript were demed by our institutional review board as exempt from human subjects research.
: Not Applicable.
: Dr. Brad Kahl discloses consulting and research funding from Roche/Genentech. Dr. Randy Gascoyne discloses consulting for Roche/Genentech. All other authors declare no competing financial interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.